Document is current

Article History

Received: 14 December 2024

Accepted: 18 November 2025

First Online: 3 March 2026

Declarations

:

: No ethical approval was required for this article.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Ahmad Jalili has been involved in consultancy, lectures and/or clinical trials for AbbVie, Almirall, Amgen , Bayer, BioMed, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galderma, GlaxoSmithKline, Incyte Biosciences, Janssen-Cilag, La Roche-Posay, LEO Pharma, Merz Pharma, MSD, Novartis, Pfizer, Sanofi, Sandoz, UCB Pharma. Roni Dodiuk-Gad has been a consultant and/or investigator for Abbvie, Dexcel, Devintec Pharma, Eli Lilly, Janssen, La Roche-Posay, Mitsubishi Tanabe Pharma America, Novartis, Pfizer, Sanofi, Sol-Gel Technologies Ltd. Melinda Gooderham has been an investigator, speaker and/or advisor for AbbVie, Acelyrin, Alumis, Amgen, Akros, Arcutis, Aristea, AnaptysBio, Apogee, Bausch Health, BMS, Boehringer Ingelheim, Cara, Dermira, Dermavant, Eli Lilly, Galderma, GSK, Incyte, InMagene, JAMP Pharma, Janssen, LEO Pharma, L’Oreal, MedImmune, Meiji, Moonlake, Nektar, Nimbus, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, Tarsus, Takeda, UCB, Union, Ventyx and Vyne. Dr Michael Ziv has served as an investigator, speaker, and consultant for AbbVie, Sanofi, Novartis, Eli Lilly, Boehringer-Ingelheim, Janssen, Pfizer, DermAbio, and Neopharm. Sofia Labbouz: none.

: All authors made substantial contributions to the conception or design of the work, drafted the work or revised it critically for important intellectual content, approved the version to be published, and agree to be accountable for all aspects of the work. All authors read and approved the final manuscript. *Based on/adapted from: ICMJE, Defining the Role of Authors and Contributors.